overlooked blind spot ............. For patients colonized with MRSA… — Medical Notes Dr. Ayman Radwan — TG.ME

overlooked blind spot ............. For patients colonized with MRSA (positive screening for pre surgical patient but no active clinical MRSA infection) decolonization bundles generally include: 1-Nasal Ointment: Mupirocin (2%) applied twice daily for 5 days. 2-Body Wash: Daily use of antiseptic washes like chlorhexidine gluconate (2%-4%) or triclosan for 5 days .............. the Trap is what to do in HAP when empirical anti MRSA and anti pseudomonal were started empirically , continued after 48 h where the nasal swab showed positive mec gene but the sputum /blood culture documented Gram negative bacilli( klebsiella or pseudomonas), would you (a) continue anti MRSA "eg IV vancomycin"=fear from macro ecosystem where MRSA IS FORCED to switch to the dormant state ,then the culture will miss it (b) discontinue vancomycin and use dual antipseudomonal according to the culture only .defer the decolonization (c) use culture based regimen with immediate decolonization "to reduce the risk of co infection" Comment Current EBM for MRSA decolonization is derived from massive, population-level ICU trials (like the REDUCE MRSA trial). These trials evaluate universal decolonization upon admission for general infection control. They are not designed with the granularity to test the specific, mechanistic scenario you are describing: initiating decolonization mid-acute HAP to prevent a subsequent mucosal breach, secondary bacteremia, and the micro-evolutionary shift to hVISA. Because no randomized controlled trial has specifically tested this exact sequence, guidelines default to conservative stewardship (deferring). this is an absence of data, leaving a valid theoretical window where targeted decontaminating could theoretically halt that specific cascade. failure of decolonization due to extranasal reservoirs (including the GI tract, throat, and perineum) is heavily documented in the literature Approximately 50–60% of patients with nasal MRSA colonization also harbor the organism in extranasal sites. The throat and the gastrointestinal tract/perineum are the most common secondary reservoirs. Clinical studies consistently show that attempting to eradicate MRSA using only nasal mupirocin frequently fails because these untreated extranasal sites (especially the throat and gut) act as persistent reservoirs that re-seed the nares. This is precisely why EBM dictates a "bundle" approach, pairing mupirocin with chlorhexidine body washes to address the skin and perineal load. During an acute systemic illness like Gram-negative sepsis or HAP, the microbiome is aggressively disrupted by broad-spectrum IV antibiotics. The concern is that attempting a topical decolonization protocol in this chaotic environment often fails to achieve true eradication, leaving the patient vulnerable to the exact translocation sequence described, regardless of the mupirocin application. we have to run a group of RCTs to access the benifit with different bacteria , medical conditions (eg DM may alter bacterial environment and behavior while allergic sinusitis may alter permeability )and antibacterials. it is a total blind spot with Gap of evidence ,also rate of co infection is not ever assessed